Medicure investor relations material

Medicure Inc. researches develops and commercializes human therapies for the cardiovascular market in the US. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. The company also sells UCERIS rectal foam for the induction of remission in patients with mild to moderate active distal ulcerative colitis, as well as develops deforolimus injection for acute myelogenous leukemia; roxadustat for anemia in chronic kidney disease; Apadenoson that is in Phase III clinical trials to diagnose coronary artery anomalies; and MC-4232, an oral endothelial receptor antagonist that is in Phase IIb clinical trial to treat congestive heart failure.